Acumen Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

De winst van Acumen Pharmaceuticals zal naar verwachting dalen met 11.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 87.2% per jaar. De winst per aandeel zal naar verwachting dalen met 7.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -116.1% zijn.

Belangrijke informatie

-11.5%

Groei van de winst

-7.1%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	87.2%
Toekomstig rendement op eigen vermogen	-116.1%
Dekking van analisten	Low
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Recent updates

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01

Winst- en omzetgroeiprognoses

NasdaqGS:ABOS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-121	-137	-141	3
12/31/2025	N/A	-119	-117	-120	4
12/31/2024	N/A	-95	-80	-80	4
9/30/2024	N/A	-82	-67	-67	N/A
6/30/2024	N/A	-65	-56	-56	N/A
3/31/2024	N/A	-56	-51	-51	N/A
12/31/2023	N/A	-52	-43	-43	N/A
9/30/2023	N/A	-49	-46	-46	N/A
6/30/2023	N/A	-46	-42	-42	N/A
3/31/2023	N/A	-45	-37	-37	N/A
12/31/2022	N/A	-43	-35	-35	N/A
9/30/2022	N/A	-38	-28	-28	N/A
6/30/2022	N/A	-32	-26	-26	N/A
3/31/2022	N/A	-83	-24	-24	N/A
12/31/2021	N/A	-101	-18	-18	N/A
9/30/2021	0	-93	-17	-17	N/A
6/30/2021	1	-92	-11	-11	N/A
3/31/2021	1	-32	-8	-8	N/A
12/31/2020	1	-7	-7	-7	N/A
12/31/2019	2	-8	-7	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ABOS de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ABOS de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ABOS de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat ABOS volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat ABOS volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ABOS binnen 3 jaar verliesgevend zal zijn.

Acumen Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 8.7% to US$10.80

Price target decreased by 8.4% to US$14.00

Price target increased by 8.6% to US$16.60

Price target decreased by 8.0% to US$14.57

Price target increased to US$17.20

Price target increased to US$16.00

Recent updates

Price target decreased by 8.7% to US$10.80

Acumen Pharmaceuticals, Inc. Appoints Amy Schacterle as Chief Regulatory Officer and Head of Quality

Acumen Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals, Inc. Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC) 2024

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Acumen Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Acumen Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Acumen Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Acumen Pharmaceuticals, Inc. Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting

Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer

Price target decreased by 8.4% to US$14.00

CEO, President & Director notifies of intention to sell stock

Price target increased by 8.6% to US$16.60

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease

Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium At the 16Th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Independent Director notifies of intention to sell stock

Acumen Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Shareholder dilution

Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Price target decreased by 8.0% to US$14.57

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of Acu193, First Monoclonal Antibody Developed to Selectively Target Toxic A<Beta> Oligomers in Patients with Early Alzheimer's Disease

Acumen Pharmaceuticals Provides Updates with Respect to INTERCEPT-AD

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to Its Board of Directors

Price target increased to US$17.20

Key Executive exercised options to buy US$273k worth of stock.

Acumen Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acumen Pharmaceuticals, Inc. Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193

Acumen Pharmaceuticals, Inc. Acu193, an Anti-Amyloid Beta Oligomer Antibody, Granted Fda Fast Track Designation for Alzheimer's Disease

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$16.00

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Acumen Pharmaceuticals, Inc. Announces Resignation of Dr. Jeffrey Sevigny to Its Board of Directors

Acumen Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from Russell 2500 Value Index

Acumen Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

Full year 2021 earnings released

Acumen Pharmaceuticals, Inc. Announces Management Changes

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.10 loss per share

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharmaceuticals, Inc. has completed an IPO in the amount of $159.999984 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven